Search results
Showing 1 to 15 of 25 results for atopic dermatitis
Dupilumab for treating moderate to severe atopic dermatitis (TA534)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.
Baricitinib for treating moderate to severe atopic dermatitis (TA681)
Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)
Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.
NICE is unable to make a recommendation on crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older because Pfizer withdrew its evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA701
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]
In development [GID-TA11349] Expected publication date: TBC
This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity.
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: TBC
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency.
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
In development [GID-TA10764] Expected publication date: TBC
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
Awaiting development [GID-TA11183] Expected publication date: TBC